Nephraegis Therapeutics

Executive Summary

Nephraegis Therapeutics is a private, preclinical-stage biotechnology company based in San Diego, California, founded in 2018. The company focuses on developing novel small molecule therapies for acute kidney injury (AKI) and chronic kidney disease (CKD), areas with significant unmet medical need. By targeting cellular energetics and metabolism pathways, Nephraegis aims to promote kidney repair and regeneration, addressing the underlying pathophysiology rather than just symptoms. Despite the high prevalence and limited treatment options for kidney diseases, current therapeutic landscape is sparse, underscoring the potential impact of Nephraegis's approach. The company remains in early development stages, with no disclosed funding rounds or clinical trials to date, reflecting the challenges typical of preclinical ventures. Its innovative strategy and experienced team, however, position it to potentially advance novel candidates toward the clinic.

Upcoming Catalysts (preview)

• TBDInitiation of IND-Enabling Studies70% success
• TBDSeries A or B Financing Round65% success
• TBDPreclinical Proof-of-Concept Data Release80% success